Location of Metastases: Leptomeningeal Disease

NCT05459441: Efficacy and Safety Evaluation of Percutaneous Ommaya Capsule Injection of Autologous Bi-dimensional Specific T Cells in the Treatment of Glioma and in Combination With Pemetrexed in the Treatment of Brain/Meningeal Metastases

NCT05459441
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Early Phase 1
Drug Category: Chemotherapy, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 80 Years (Adult, Older Adult)
Location of Metastases: Brain, Leptomeningeal Disease
Additional Notes: Patients must have brain metastasis & relapsed after surgery, whole brain radiotherapy or chemotherapy
Exclusions: Patients with brain metastasis who are suitable for surgery or radiotherapy after having a relapse; Patients with systemic metastasis (outside of the brain)
https://ClinicalTrials.gov/show/NCT05459441

NCT05414123: A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide

NCT05414123
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: Brain, Leptomeningeal Disease 
Additional Notes: Patients must have clinically suspected leptomeningeal disease
Exclusions: 
https://ClinicalTrials.gov/show/NCT05414123

Up ↑